CD8A and cancer: Accordingly, pharmacological inhibition of IGF1 receptor (IGF1R) by two different small molecules, picropodophyllin and linsitinib, suffices to trigger autophagy in cancer cells, to augment the CD8/FOXP3 ratio in tumor-infiltrating lymphocytes, and to enhance therapeutic responses to chemotherapy and immunotherapy (8).